Oligoprogression During First-Line Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Comparative Outcomes of Metastasis-Directed Radiotherapy and Systemic Treatment Change
In patients with mHSPC who developed oligoprogression during first-line systemic therapy, metastasis-directed RT with continuation of the same regimen and immediate change in systemic treatment were associated with comparable post-oligoprogression outcomes in our cohort. These findings suggest that both strategies may be feasible in selected patients. Prospective studies may help clarify which patients are more likely to benefit from each strategy.
Authors
- Murat Günaltılı (ORCID: https://orcid.org/0000-0001-6116-3936)
- Özkan Alan (ORCID: https://orcid.org/0000-0002-6635-2012)
- Hamza Abbasov (ORCID: https://orcid.org/0000-0003-1227-9996)
- Murad Guliyev (ORCID: https://orcid.org/0000-0002-2981-8098)
- Seda Jeral (ORCID: https://orcid.org/0000-0002-6594-1712)
- Emir Çerme (ORCID: https://orcid.org/0000-0002-8263-0692)
- Nebi Serkan Demirci (ORCID: https://orcid.org/0000-0001-5943-889X)
- Süheyla Atak (ORCID: https://orcid.org/0000-0002-4136-0091)
- Halil Cumhur Yıldırım (ORCID: https://orcid.org/0000-0002-1412-1933)
- Zeliha Birsin
- FO Dinçbas
- Vali Aliyev (ORCID: https://orcid.org/0000-0003-0947-9348)
- Selin Cebeci (ORCID: https://orcid.org/0000-0002-1758-2321)
- Ebru Çiçek
Institutions
- Istanbul University-Cerrahpaşa (TR)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-04-17
- DOI
- https://doi.org/10.3390/jcm15083067
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00